Royalty Report: Drugs, Disease, Therapeutic – Collection: 7325

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Supply
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7325

License Grant
In this collaboration agreement the Licensor granted the Licensee exclusive rights to develop and commercialize Xiaflex for the treatment of Dupuytren's contracture and Peyronie's disease in Canada, Australia, Brazil and Mexico upon receipt of the applicable regulatory approvals.

The Licensee was also granted the right of first negotiation to obtain exclusive rights to commercialize any new Xiaflex indications in the Licensee Territory during the term of the Agreement.

License Property
XIAFLEX is a collagenase clostridium histolyticum for the treatment of adult Dupuytren’s contracture (Dupuytren’s) patients with a palpable cord and Peyronie’s disease.

Dupuytren's contracture (also known as morbus Dupuytren, or Dupuytren's disease),[1] is a fixed flexion contracture of the hand due to a palmar fibromatosis,[2] where the fingers bend towards the palm and cannot be fully extended (straightened). It is an inherited proliferative connective tissue disorder which involves the palmar fascia of the hand.
Peyronie's disease or Peyronie disease (/pe?ro?'ni?/), also known as induratio penis plastica (IPP)[1] or chronic inflammation of the tunica albuginea (CITA), is a connective tissue disorder involving the growth of fibrous plaques[2] in the soft tissue of the penis affecting 5% of men.

Field of Use
Peyronie's disease is the development of fibrous scar tissue inside the penis that causes curved, painful erections. Dupuytren's contracture is a hand deformity that usually develops slowly, over years. Dupuytren's contracture affects a layer of tissue that lies under the skin of your palm. Knots of tissue form under the skin – eventually forming a thick cord that can pull one or more of your fingers into a bent position.

IPSCIO Record ID: 4349

License Grant
The Licensor granted the Licensee the right to develop and commercialize, with the right to sublicense, Xiapex (EU tradename for Xiaflex) for the treatment of Peyronie's and Dupuytren's upon receipt of the applicable regulatory approvals in the 27 member countries of the EU as it existed as of the effective date of the Agreement.  

The Licensor and the Licensee entered into an amendment to the Development, Commercialization and Supply Agreement, dated as of December 17, 2008, by and among the Parties regarding their collaboration agreement for the development, commercialization and supply of Xiapex in the European Union and certain other European and Eurasian countries.

License Property
Xiapex® (collagenase clostridium histolyticum), is a licensed injectable treatment option for Dupuytren's contracture in adult patients with a palpable cord.

After the Termination Date, all rights held by the Licensee to commercialize Xiapex and the responsibility for regulatory activities for Xiapex in the aforementioned countries will revert, at no cost, to the Licensor.

The treatment involves injecting Xiapex into the Dupuytren’s cord. Xiapex uses a precise enzymatic action that dissolves collagen in the cord.

Field of Use
The Licensee received marketing authorization by the European Commission on February 28, 2011 and Xiapex is now available in Austria, Denmark, Finland, Norway, Spain, Switzerland, Sweden, and the UK.

The Licensee is required to obtain Xiapex exclusively from the Licensor.  

The Licensee is solely responsible for commercializing Xiapex in the Territory during the term of the Agreement and is solely responsible for costs associated with commercializing Xiapex in the Territory.

After the Termination Date, all rights held by the Licensee  will revert, at no cost, to the Licensor.  

Dupuytren's disease is a slowly progressive condition affecting the layer of connective tissue in the palm of the hand and the fingers (the palmar fascia).

IPSCIO Record ID: 2999

License Grant
The Licensee entered into a license agreement with a Research Foundation which granted to us and our affiliates an exclusive worldwide license, with the right to sublicense to certain third parties, to know-how owned by the Research Foundation related to the development, manufacture, use or sale of the collagenase enzyme obtained by a fermentation and purification process, and all pharmaceutical products containing the Enzyme or injectable collagenase, in each case to the extent it pertains to the treatment and prevention of Dupuytren's contracture. Our obligation to pay royalties to the Research Foundation with respect to sales by the Company, its affiliates or any sublicensee of any Dupuytren's Licensed Product in any country (including the U.S.) arises only upon the first commercial sale of such Dupuytren's Licensed Product on a country-by-country basis. Our obligation to pay royalties will continue until the later of the expiration of the last valid claim of a patent pertaining to the Dupuytren's Licensed Product; the expiration of the regulatory exclusivity period conveyed by the FDA's Orphan Product Division with respect to the Dupuytren's Licensed Product; or June 3, 2016.
Field of Use
The Licensee will pay a royalty on net sales of Xiaflex TM for the treatment and prevention of Dupuytren’s disease.  After that, all licenses granted to us under the Dupuytren's License Agreement will become fully paid, irrevocable exclusive licenses.

IPSCIO Record ID: 7323

License Grant
Under the Agreement, the Licensee has exclusive worldwide rights to develop, market and sell certain products containing the collagenase enzyme, which the Licensee refers to as Xiaflex.
License Property
The Licensed rights concern the development and commercialization of products, other than dermal formulations labeled for topical administration, and currently, our Licensed rights cover the indications of Dupuytren’s, Peyronie’s, Frozen Shoulder syndrome and, upon our optional payment of $500,000 to the Licensor, cellulite.
Field of Use
The Licensee is responsible, at our own cost and expense, for developing the formulation and finished dosage form of products and arranging for the clinical supply of products.  

Under the Agreement, the Licensee has the exclusive right to manufacture any pharmaceutical product containing the collagenase enzyme as an active ingredient:
· for the indications of Dupuytren’s, Peyronie’s and Frozen Shoulder syndrome, and for any indications outside the Field which the Licensor elects not to pursue; and
. for early-stage development activities through phase II clinical trials for any indications.

The Licensee has the non-exclusive right to manufacture any pharmaceutical product containing the collagenase enzyme as an active ingredient:
·  for supply to the Licensor for in vitro development; and
·  for post-phase II development (including submissions for regulatory approval) and commercialization of indications outside the Field which Licensee elects not to pursue.

The Licensee is responsible, at our cost, for performing early stage development activities for the treatment of edematous fibrosclerotic panniculopathy, more commonly known as cellulite. The Licensor has granted us an exclusive License to research, develop, manufacture and use Xiaflex in connection with this development.

IPSCIO Record ID: 44080

License Grant
The Irish Company, through an affiliate, is party to a development and license agreement, as amended, to obtain exclusive worldwide rights to develop, market and sell certain products containing Licensors enzyme, which we refer to as XIAFLEX® (Xiapex® in the European Union).
License Property
Xiaflex is a brand name for collagenase, a naturally occurring enzyme that is involved in tissue repair.
Field of Use
The licensed rights concern the development and commercialization of products for the treatment of Dupuytren’s contracture (DC), Peyronie’s Disease (PD), Adhesive Capsulitis (aka, Frozen Shoulder syndrome), cellulite, and canine lipoma, but specifically excluding, dermal formulations labeled for topical administration.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.